Hypertensive nephropathy Medical Services in China

Hypertensive nephropathy, also known as hypertensive kidney disease or chronic hypertensive nephrosclerosis, is a progressive form of chronic kidney disease (CKD) resulting from long-standing, uncontrolled arterial hypertension. It is characterized by structural and functional damage to the renal microvasculature—particularly arterioles and glomeruli—leading to glomerulosclerosis, tubulointerstitial fibrosis, and eventual decline in glomerular filtration rate (GFR). Pathogenesis centers on hemodynamic stress: sustained high systemic pressure causes endothelial injury, vascular smooth muscle hypertrophy, hyaline arteriolosclerosis, and ischemic glomerular damage. Over time, this triggers inflammatory cascades, oxidative stress, renin-angiotensin-aldosterone system (RAAS) overactivation, and profibrotic signaling (e.g., TGF-β), culminating in irreversible scarring. Unlike acute hypertensive emergencies, hypertensive nephropathy develops insidiously over years or decades, often without early symptoms. Epidemiologically, it accounts for approximately 10–25% of end-stage kidney disease (ESKD) cases globally and is among the top three causes of CKD in China—especially prevalent in adults aged 50–75 years. Hypertension affects over 270 million adults in China, and roughly 15–20% of those with stage 2+ hypertension develop clinically significant kidney impairment within 10–15 years if untreated. Key modifiable risk factors include persistent systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg, poor antihypertensive adherence, diabetes mellitus (which synergistically accelerates renal injury), obesity, smoking, high-sodium diet, and sedentary lifestyle. Non-modifiable risks include older age, male sex, African or East Asian ancestry, and family history of hypertension or CKD. Quality of life is significantly impaired as disease advances: patients commonly experience fatigue, nocturia, reduced exercise tolerance, sleep disturbances, anxiety about dialysis or transplant, and socioeconomic strain due to treatment burden and work limitations. Early-stage disease may be asymptomatic, delaying diagnosis; later stages bring edema, shortness of breath (from fluid overload), cognitive fog, and increased cardiovascular mortality—making hypertensive nephropathy not only a renal disorder but a major driver of overall morbidity and premature death. Timely detection via routine urinalysis (microalbuminuria), serum creatinine/eGFR monitoring, and renal ultrasound is critical. Management hinges on rigorous blood pressure control (<130/80 mmHg for most CKD patients), RAAS blockade (ACE inhibitors or ARBs), sodium restriction (<2 g/day), and integrated cardiovascular risk reduction.

Hypertensive nephropathy—also termed hypertensive kidney disease or chronic hypertensive nephrosclerosis—is a progressive renal disorder resulting from long-standing, uncontrolled systemic arterial hypertension. It is characterized by arteriolar hyalinosis, glomerulosclerosis, tubulointerstitial fibrosis, and eventual decline in glomerular filtration rate (GFR). Early detection and rigorous blood pressure (BP) control are paramount to slowing disease progression and preventing end-stage kidney disease (ESKD). Management is multidisciplinary, with nephrology playing a central role in diagnosis, risk stratification, and longitudinal care.

Conservative treatment forms the cornerstone of management and emphasizes non-pharmacologic interventions aimed at mitigating cardiovascular and renal risk. Lifestyle modification is evidence-based and includes sustained sodium restriction (<2 g/day), adherence to the DASH (Dietary Approaches to Stop Hypertension) or Mediterranean diet rich in fruits, vegetables, whole grains, and low-fat dairy, while limiting processed foods and added sugars. Weight reduction (target BMI 18.5–24.9 kg/m²) is recommended for overweight or obese individuals, as each 1 kg weight loss correlates with ~1 mmHg systolic BP reduction. Regular aerobic exercise (≥150 minutes/week of moderate-intensity activity) improves endothelial function and insulin sensitivity. Smoking cessation is mandatory, given its synergistic effect on vascular injury and accelerated glomerulosclerosis. Alcohol intake should be limited to ≤14 units/week for men and ≤7 units/week for women. Additionally, patients must avoid nephrotoxic agents—including NSAIDs, intravenous contrast media (unless absolutely indicated with hydration protocols), and herbal nephrotoxins (e.g., aristolochic acid-containing preparations). Annual monitoring of urinary albumin-to-creatinine ratio (UACR), serum creatinine, estimated GFR (eGFR), electrolytes, and renal ultrasound is essential for early detection of microalbuminuria or structural changes.

Pharmacologic therapy targets both BP control and renoprotection. Current guidelines (KDIGO 2021, AHA/ACC 2017, and China’s 2023 Guidelines for Hypertension and Chronic Kidney Disease) recommend a BP goal of <130/80 mmHg for most adults with hypertensive nephropathy and CKD stages G1–G4, provided it is tolerated without symptomatic hypotension or acute kidney injury. First-line antihypertensives include angiotensin-converting enzyme inhibitors (ACEIs; e.g., ramipril, perindopril) or angiotensin II receptor blockers (ARBs; e.g., losartan, valsartan), which reduce intraglomerular pressure, decrease proteinuria, and slow fibrotic progression—even in non-diabetic hypertensive nephropathy. Dual RAS blockade is contraindicated due to increased risk of hyperkalemia, acute kidney injury, and mortality. If BP remains uncontrolled, calcium channel blockers (CCBs; particularly nondihydropyridines like diltiazem or verapamil, or long-acting dihydropyridines such as amlodipine) are preferred second-line agents. Thiazide-like diuretics (e.g., chlorthalidone or indapamide) are effective in volume-overloaded patients and enhance ACEI/ARB efficacy. For resistant hypertension, low-dose spironolactone (12.5–25 mg/day) may be added cautiously—with strict monitoring of potassium and creatinine—but is avoided if eGFR <45 mL/min/1.73m² or baseline K⁺ >4.5 mmol/L. Beta-blockers are reserved for comorbid indications (e.g., heart failure, post-MI) rather than primary renal protection. In advanced CKD (eGFR <30 mL/min/1.73m²), loop diuretics (e.g., furosemide, torsemide) replace thiazides, and dose adjustments are guided by renal clearance.

Surgical treatment has no primary role in hypertensive nephropathy itself, as it is not a surgically correctable condition. However, secondary causes of hypertension—such as renal artery stenosis (RAS), pheochromocytoma, or primary aldosteronism—must be excluded, especially in cases of early-onset, resistant, or rapidly deteriorating hypertension with renal impairment. When hemodynamically significant atherosclerotic RAS (>70% stenosis with ischemic nephropathy or flash pulmonary edema) is confirmed via CTA/MRA and functional testing (e.g., captopril renography or renal vein renin sampling), revascularization (endovascular stenting or surgical bypass) may be considered in select patients under rigorous multidisciplinary evaluation. Nevertheless, recent trials (e.g., CORAL, STAR) demonstrate no incremental renal or cardiovascular benefit over optimal medical therapy alone in most patients; thus, intervention is now restricted to highly selected cases with recurrent unexplained heart failure or progressive renal dysfunction attributable to unilateral RAS. Nephrectomy is exceedingly rare and only contemplated in end-stage unilateral disease with refractory hypertension or infection.

China offers distinct advantages in the comprehensive management of hypertensive nephropathy. First, the national tiered healthcare system enables seamless referral from community health centers—where standardized BP screening, home BP monitoring programs, and nurse-led education are widely implemented—to tertiary nephrology centers equipped with advanced diagnostics (e.g., renal biopsy, genetic testing for monogenic hypertension, and AI-assisted imaging analysis). Second, China’s large-scale real-world registries (e.g., the China Kidney Disease Network, CK-NET) inform localized treatment algorithms and facilitate rapid translation of evidence into practice. Third, cost-effective generic formulations of ACEIs, ARBs, CCBs, and diuretics are universally accessible through the National Reimbursement Drug List (NRDL), significantly improving medication adherence. Fourth, integrated traditional Chinese medicine (TCM) adjuncts—such as Huangkui capsule (for proteinuria reduction) and Shenyan Kangfu tablets (for symptom control)—are rigorously evaluated in randomized controlled trials and incorporated into clinical pathways when supported by Level I evidence. Finally, digital health innovations—including AI-powered BP prediction models, tele-nephrology platforms for rural follow-up, and WeChat-based patient education modules—enhance continuity of care across geographically dispersed populations.

Recovery and long-term prognosis depend on sustained BP control, avoidance of nephrotoxic exposures, and proactive complication management. Patients should perform home BP monitoring twice daily (morning and evening) using validated upper-arm devices and maintain a log shared during clinic visits. Annual ophthalmologic exams screen for hypertensive retinopathy; echocardiography assesses left ventricular hypertrophy; and lipid profiles and HbA1c guide cardiovascular risk mitigation. Vaccination against influenza, pneumococcus, and hepatitis B is strongly encouraged. As renal function declines, dietary protein intake should be moderated (0.6–0.8 g/kg/day in CKD G3b–G5, with high biological value sources) under dietitian supervision to reduce uremic toxin accumulation without inducing malnutrition. Psychosocial support—including counseling for depression/anxiety, which affects up to 30% of CKD patients—is integral to holistic recovery. Ultimately, successful management hinges on patient empowerment: understanding disease trajectory, recognizing red-flag symptoms (e.g., sudden edema, dyspnea, oliguria), and active participation in shared decision-making. With early intervention and consistent multidisciplinary care, many patients maintain stable renal function for decades, avoiding dialysis and preserving quality of life.